(Drug Name) (Drug Form) (Drug Strength)
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • myWeekly Ad

ORBACTIV: Lyophilisate for solution for injection (449mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png


What is this Medicine?

ORITAVANCIN (ORE ita van sin) is an antibiotic. It is used to treat certain kinds of bacterial infections. It will not work for colds, flu, or other viral infections.

In-Depth Information

Orbactiv 400mg Powder for Injection

NDC: 652930015
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Cellulitis, Erysipelas, Skin And Skin Structure Infections

Storage Information
Store unreconstituted product at 68 to 77 degrees F; excursions permitted to 59 to 86 degrees F
Discard product if it contains particulate matter, is cloudy, or discolored
Discard unused portion. Do not store for later use.
Orbactiv 400mg Powder for Injection

Reported Side Effects for Orbactiv 400mg Powder for Injection

Skin Rash Incidence:
<1.5%*
Severity: MILD
Onset: EARLY
Skin Redness Incidence:
<1.5%*
Severity: MODERATE
Onset: EARLY
Eosinophilia Incidence:
<1.5%*
Severity: MODERATE
Onset: DELAYED
Breathing Difficulties Incidence:
<1.5%*
Severity: SEVERE
Onset: RAPID
Joint Inflammation Incidence:
<1.5%*
Severity: MODERATE
Onset: DELAYED
Inflamed Blood Vessels Incidence:
<1.5%*
Severity: SEVERE
Onset: DELAYED
Fluid Retention Incidence:
<1.5%*
Severity: MODERATE
Onset: DELAYED
Hives Incidence:
<1.5%*
Severity: MILD
Onset: RAPID
Itching Incidence:
<1.5%*
Severity: MILD
Onset: RAPID
Muscle Pain Incidence:
<1.5%*
Severity: MILD
Onset: EARLY
Low Blood Sugar Incidence:
<1.5%*
Severity: MODERATE
Onset: EARLY
High Uric Acid Level Incidence:
<1.5%*
Severity: MODERATE
Onset: DELAYED
Wheezing Incidence:
<1.5%*
Severity: MODERATE
Onset: RAPID
Erythema Multiforme Incidence:
<1.5%*
Severity: SEVERE
Onset: DELAYED
Angioedema Incidence:
<1.5%*
Severity: SEVERE
Onset: RAPID
Anemia Incidence:
<1.5%*
Severity: MODERATE
Onset: DELAYED
Osteomyelitis Incidence:
0.3%*
Severity: MODERATE
Onset: DELAYED
Infection Incidence:
0.3-0.4%*
Severity: MILD
Onset: DELAYED
Elevated Hepatic Enzymes Incidence:
1.8-2.8%*
Severity: MODERATE
Onset: DELAYED
Infusion-related Reactions Incidence:
1.9%*
Severity: MODERATE
Onset: RAPID
Irritated Blood Vessels Incidence:
2.5%*
Severity: MODERATE
Onset: RAPID
Rapid Heart Rate Incidence:
2.5%*
Severity: MODERATE
Onset: RAPID
Lightheadedness Incidence:
2.7%*
Severity: MILD
Onset: EARLY
Loose Stools Incidence:
3.7%*
Severity: MILD
Onset: EARLY
Vomiting Incidence:
4.6%*
Severity: MILD
Onset: EARLY
Headache Incidence:
7.1%*
Severity: MILD
Onset: EARLY
Upset Stomach Incidence:
9.9%*
Severity: MILD
Onset: EARLY
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

SECOND Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

THIRD Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

Lactation

Caution - Not enough information is available to rule out harm to infants when this drug is taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with ORBACTIV

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5